May 23, 2018
BMJ: United States’ FDA providing insufficient information on post-approval drug effectiveness.
BMJ: United States’ FDA providing insufficient information on post-approval drug effectiveness.
Another look at the opioid crisis – this time in the justice system.
When Insurance Interferes In Your Good Care “Last September, Kathy Halamka received a letter from her health insurance company stating that it was discontinuing coverage for her ongoing cancer care because the payer had come across research published 27 years ago suggesting that a different, less expensive treatment was better. The insurer took this action […]
‘End Of Life’ Medical Ethics
#QualityFraud WaPo: Rare Disease Jackpot for Healthcare Industry and Pharma
WaPo: A Genuine Solution To Our Healthcare Problem
ACA Gains Lost While Politicians Do Nothing
#QualityFraud Vox: She didn’t get treated at the ER. But she got a $5,751 bill anyway.
#QualityFraud NYT: Opioids Making A Fortune For Pharma And Prescribers
CMS Proposing To Allow Direct Physician Billing